At a glance
- Originator Aventis
- Class Antibacterials
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 05 Aug 1998 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 14 Nov 1996 Preclinical development for Bacterial infections in USA (Unknown route)